Mosunetuzumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NICE (England) recommended or restricted mosunetuzumab, while NYE METODER (Norway) and SMC (Scotland) did not recommend it.
The record spans 4.2 years, opening at AWMSG (Wales) on 27 May 2022 and running to 13 Aug 2026.
AOTMIT (Poland) changed its position: not recommended on 22 Feb 2024, restricted by 13 Aug 2026, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), PBAC (Australia) and PHARMAC (New Zealand) among them — hold no record for mosunetuzumab at all.
The file is active: 9 of 10 records date from 2023 or later.
Against its own class, mosunetuzumab is an outlier: 38% of its decisive outcomes were positive, where molecules sharing ATC class L01F average 73%.
3 distinct indication wordings are recorded for mosunetuzumab by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess mosunetuzumab, on 27 May 2022; NYE METODER (Norway) did not open a file until 27 Apr 2025 — a moderate spread of 2.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
Restriction is doing real work here: 2 of 8 decisive outcomes narrowed mosunetuzumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland) and NICE (England).
2 of the 7 agencies here assessed mosunetuzumab more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for mosunetuzumab.
The full ledger for mosunetuzumab reads 5 not recommended, 2 restricted, 1 pending and 1 recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 28 Apr 2026 | Indicación terapéutica autorizada: Lunsumio como monoterapia está indicado para el tratamiento de pacientes adultos con … | not financed by the SNS · art. 92 d | source |
| NYE METODER (Norway) | 27 Apr 2025 | Monoterapi til behandling av voksne med residivert eller refraktært follikulært lymfom (FL) som har fått minst to tidlig… | not introduced | source |
| CHUIKYO (Japan) | 12 Mar 2025 | ルンスミオ: cost-effectiveness evaluation (designated at listing) | designated, analysis not started | source |
| AOTMIT (Poland) | 22 Feb 2024 | programu lekowego „Leczenie chorych na chłoniaki B- komórkowe (ICD-10: C82, C83, C85) | not recommended | source |
| SMC (Scotland) | 11 Sep 2023 | As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. | not recommended | source |
5 further decisions for mosunetuzumab, across 4 agencies, are not shown here. They include the most recent record on file, 13 Aug 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 10 decisions for mosunetuzumab from 7 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.